Shaloam Dasari1, Paul Bernard Tchounwou2. 1. Cellomics and Toxicogenomics Research Laboratory, NIH/NIMHD RCMI-Center for Environmental Health, College of Science, Engineering and Technology, Jackson State University, 1400 Lynch Street, Box 18750, Jackson, MS 39217, USA. 2. Cellomics and Toxicogenomics Research Laboratory, NIH/NIMHD RCMI-Center for Environmental Health, College of Science, Engineering and Technology, Jackson State University, 1400 Lynch Street, Box 18750, Jackson, MS 39217, USA. Electronic address: paul.b.tchounwou@jsums.edu.
Abstract
Cisplatin, cisplatinum, or cis-diamminedichloroplatinum (II), is a well-known chemotherapeutic drug. It has been used for treatment of numerous human cancers including bladder, head and neck, lung, ovarian, and testicular cancers. It is effective against various types of cancers, including carcinomas, germ cell tumors, lymphomas, and sarcomas. Its mode of action has been linked to its ability to crosslink with the purine bases on the DNA; interfering with DNA repair mechanisms, causing DNA damage, and subsequently inducing apoptosis in cancer cells. However, because of drug resistance and numerous undesirable side effects such as severe kidney problems, allergic reactions, decrease immunity to infections, gastrointestinal disorders, hemorrhage, and hearing loss especially in younger patients, other platinum-containing anti-cancer drugs such as carboplatin, oxaliplatin and others, have also been used. Furthermore, combination therapies of cisplatin with other drugs have been highly considered to overcome drug-resistance and reduce toxicity. This comprehensive review highlights the physicochemical properties of cisplatin and related platinum-based drugs, and discusses its uses (either alone or in combination with other drugs) for the treatment of various human cancers. A special attention is paid to its molecular mechanisms of action, and its undesirable side effects.
Cisplatin, n class="Chemical">cisplatinum, or cis-diamminedichloroplatinum (II), is a well-known chemotherapeutic drug. It has been used for treatment of numerous human cancers including bladder, head and neck, lung, ovarian, and testicular cancers. It is effective against various types of cancers, including carcinomas, germ cell tumors, lymphomas, and sarcomas. Its mode of action has been linked to its ability to crosslink with the purine bases on the DNA; interfering with DNA repair mechanisms, causing DNA damage, and subsequently inducing apoptosis in cancer cells. However, because of drug resistance and numerous undesirable side effects such as severe kidney problems, allergic reactions, decrease immunity to infections, gastrointestinal disorders, hemorrhage, and hearing loss especially in younger patients, other platinum-containing anti-cancer drugs such as carboplatin, oxaliplatin and others, have also been used. Furthermore, combination therapies of cisplatin with other drugs have been highly considered to overcome drug-resistance and reduce toxicity. This comprehensive review highlights the physicochemical properties of cisplatin and related platinum-based drugs, and discusses its uses (either alone or in combination with other drugs) for the treatment of various humancancers. A special attention is paid to its molecular mechanisms of action, and its undesirable side effects.
Authors: Juan Valle; Harpreet Wasan; Daniel H Palmer; David Cunningham; Alan Anthoney; Anthony Maraveyas; Srinivasan Madhusudan; Tim Iveson; Sharon Hughes; Stephen P Pereira; Michael Roughton; John Bridgewater Journal: N Engl J Med Date: 2010-04-08 Impact factor: 91.245
Authors: Ana Cuadrado; Vanesa Lafarga; Peter C F Cheung; Ignacio Dolado; Susana Llanos; Philip Cohen; Angel R Nebreda Journal: EMBO J Date: 2007-03-22 Impact factor: 11.598
Authors: Míriam Tarrado-Castellarnau; Roldán Cortés; Miriam Zanuy; Josep Tarragó-Celada; Ibrahim H Polat; Richard Hill; Teresa W M Fan; Wolfgang Link; Marta Cascante Journal: Pharmacol Res Date: 2015-11-04 Impact factor: 7.658
Authors: Katharine Fernandez; Katie K Spielbauer; Aaron Rusheen; Lizhen Wang; Tiffany G Baker; Stephen Eyles; Lisa L Cunningham Journal: Hear Res Date: 2020-02-06 Impact factor: 3.208
Authors: Jing Gong; Sanjeev Noel; Joshua Hsu; Errol L Bush; Lois J Arend; Mohanraj Sadasivam; Sul A Lee; Johanna T Kurzhagen; Abdel Rahim A Hamad; Hamid Rabb Journal: Am J Physiol Renal Physiol Date: 2020-04-13
Authors: Si-Si Wang; Maike Zimmermann; Hongyong Zhang; Tzu-Yin Lin; Michael Malfatti; Kurt Haack; Kenneth W Turteltaub; George D Cimino; Ralph de Vere White; Chong-Xian Pan; Paul T Henderson Journal: Int J Cancer Date: 2017-05-15 Impact factor: 7.396